IMAB - As U.S. Takes Aim At China Drug Makers Innovators Appear At Biggest Risk
- In these troubled times of U.S.-China tensions, sometimes being a copycat has its benefits.
- The vast majority of the many publicly listed drug makers in China are essentially copycats that license mature drugs from other, mostly western, developers to sell in China.
- The big news came in a Friday announcement from the U.S. Commerce Department, which said it was adding 37 companies to its entity list.
For further details see:
As U.S. Takes Aim At China Drug Makers, Innovators Appear At Biggest Risk